49 filings
8-K
NKGN
NKGen Biotech Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
NKGN
NKGen Biotech Inc
24 Apr 24
Entry into a Material Definitive Agreement
7:51pm
8-K
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
NKGN
NKGen Biotech Inc
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
NKGN
NKGen Biotech Inc
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
jjskobl7w2 1p
20 Mar 24
Other Events
4:01pm
8-K
nim3u
15 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:02pm
8-K
0mkqin0ux8qa6h
22 Feb 24
Entry into a Material Definitive Agreement
4:01pm
8-K
g7z5s1a
16 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:00pm
8-K
l21ltv
12 Feb 24
Entry into a Material Definitive Agreement
9:25am
8-K
pd3shvoevwgvt ctii
8 Feb 24
Departure of Directors or Certain Officers
5:07pm
8-K
s1nsj it4
22 Jan 24
Entry into a Material Definitive Agreement
6:12am
8-K
sof83y6
11 Jan 24
Entry into a Material Definitive Agreement
7:50pm
8-K
e8vevz
8 Jan 24
Entry into a Material Definitive Agreement
5:19pm
8-K
20ybdg
28 Dec 23
Other Events
4:14pm
8-K
4l49ta179qe76 fdj0qd
27 Dec 23
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
4:02pm
8-K
cbosmapiuzk
27 Dec 23
Entry into a Material Definitive Agreement
4:01pm
8-K
xww2mh2 mvxva
14 Nov 23
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
4:36pm
8-K
jimp1wy 691uxecizck
30 Oct 23
Regulation FD Disclosure
8:05am
8-K
vj8178as1c7 e4f7t9bf
24 Oct 23
Other Events
8:05am